drug adverse effects of COX-2-specific inhibitors
Jump to navigation
Jump to search
Adverse effects
- hypertension (especially systolic hypertension)
- diminished renal function
- peripheral edema
- heart failure
- cardiovascular disease[5]
- GI complications less frequent than with non-selective NSAIDs[6]
- GI bleed, gastritis, peptic ulcer
- combining COX-2 inhibitor with proton pump inhibitor is the most effective strategy to reduce the risk of peptic ulcer complications with NSAID therapy[8]
* safe in patients with aspirin-exacerbated respiratory disease[7]
More general terms
References
- ↑ Prescriber's Letter 7(10):55 2000
- ↑ Prescriber's Letter 8(6):31-32 2001
- ↑ Journal Watch 23(13):103, 2003 Spiegel BMR et al, Ann Intern Med 138:795, 2003
- ↑ Prescriber's Letter 11(11): 2004 Safety of COX-2 Inhibitors and Their Place in Therapy Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=201102&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 5.0 5.1 5.2 Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006 Jun 3;332(7553):1302-8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16740558
- ↑ 6.0 6.1 Cryer B et al. GI-REASONS: A novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol 2013 Mar; 108:392. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23399552
- ↑ 7.0 7.1 Morales DR et al. Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials. J Allergy Clin Immunol 2014 Jul; 134:40 PMID: https://www.ncbi.nlm.nih.gov/pubmed/24388008
- ↑ 8.0 8.1 Yuan JQ et al. Systematic review with network meta-analysis: Comparative effectiveness and safety of strategies for preventing NSAID- associated gastrointestinal toxicity. Aliment Pharmacol Ther 2016 Jun; 43:1262 PMID: https://www.ncbi.nlm.nih.gov/pubmed/27121479